A Phase 3 interventional study of ARGX-113 in Generalized Myasthenia Gravis, sponsored by argenx. Completed at 52 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-14.
Sponsored by argenx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 10 in phase 3, and was the 3rd registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:
argenx · Sites in United States, Belgium, Germany and 5 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 65+
argenx · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18+
Clinique Neuro-Outaouais · Sites in Canada
Ages 18–80
By country, each count listing its studies:
efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 4
First in 2016; this study’s year is marked. 1 started in 2019.
This study's enrollment of 151 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 55 across the 20 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 8 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
18 studies in Myasthenia Gravis by argenx: 9 open now, 12 under way, 5 of them phase 3. Of 6 finished, 6 (100%) have results posted.
Among the 18 studies in Myasthenia Gravis by argenx, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2019, is one of 7 in phase 3, and was the 3rd registered.
argenx’s Myasthenia Gravis studies by the year they started, since 2016.
7 of the studies testing efgartigimod alfa in Myasthenia Gravis that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06765161Phase 3Clinique Neuro-OutaouaisEfgartigimod in IVIG Dependent Myasthenia Gravis Patients | 2027-01-06 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT07231523Phase 3Shanghai Zhongshan HospitalEFG vs IVIG in TAMG | 2027-06-01 |
| NCT06392386Phase 3argenxA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | 2027-09 |
| NCT06221501Shanghai Zhongshan HospitalPerioperative Efgartigimod for Thymoma and Myasthenia Gravis | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among argenx’s 18 in Myasthenia Gravis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG. Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to receive efgartigimod by SC administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other more specific inclusion criteria are further defined in the protocol.
Exclusion Criteria:
Other, more specific exclusion criteria are further defined in the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ARGX-113
Intravenous administration of ARGX-113
Also known as: efgartigimod
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in AChR-Positive Participants
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any clinically significant abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (electrocardiogram \[ECG\], radiological scans, vital signs measurements) were collected as AEs. All AEs starting on or after first dose administered and until completion of participant's last visit were considered as TEAEs. A serious AE (SAE) was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant.
Time frame: TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years
Number of Participants With TEAEs, Treatment-Emergent SAEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in the Overall Population
Overall population included both AChR-Ab seropositive and AChR-Ab seronegative participants. An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any clinically significant abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (ECG, radiological scans, vital signs measurements) were collected as AEs. All AEs starting on or after first dose administered and until completion of participant's last visit were considered as TEAEs. An SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant.
Time frame: TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years
This Phase III, open-label study was a follow-on study of ARGX-113-1704 (NCT03669588) and was conducted in participants with myasthenia gravis having generalized muscle weakness at 51 investigational sites in 14 countries between 01 Mar 2019 and 30 Jun 2022. This study was conducted in 2 sequential parts: Part A (1 year) and Part B (\<=2 years).
| Milestone | Efgartigimod |
|---|---|
| Started | 145 |
| Completed | 28 |
| Not completed | 117 |
| Withdrew: Adverse event | 8 |
| Withdrew: Death | 5 |
| Withdrew: Physician decision | 1 |
| Withdrew: Sponsor decision | 1 |
| Withdrew: Study terminated by sponsor | 1 |
| Withdrew: Withdrawal by subject | 13 |
| Withdrew: Other | 88 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any clinically significant abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (electrocardiogram \[ECG\], radiological scans, vital signs measurements) were collected as AEs. All AEs starting on or after first dose administered and until completion of participant's last visit were considered as TEAEs. A serious AE (SAE) was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant.
| Participants | Efgartigimod |
|---|---|
| TEAE | 92 |
| Treatment-emergent SAE | 28 |
| TEAEs leading to study drug discontinuation | 10 |
| Fatal TEAE | 4 |
Overall population included both AChR-Ab seropositive and AChR-Ab seronegative participants. An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any clinically significant abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (ECG, radiological scans, vital signs measurements) were collected as AEs. All AEs starting on or after first dose administered and until completion of participant's last visit were considered as TEAEs. An SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant.
| Participants | Efgartigimod |
|---|---|
| TEAE | 124 |
| Treatment-emergent SAE | 36 |
| TEAEs leading to study drug discontinuation | 12 |
| Fatal TEAE | 5 |
Collected over TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod | 5/145 (3.4%) | 36/145 (24.8%) | 83/145 (57.2%) |
| Event | Efgartigimod |
|---|---|
| Myasthenia gravisNervous system disorders | 7/145 |
| Cardiac failure congestiveCardiac disorders | 2/145 |
| COVID-19Infections and infestations | 2/145 |
| COVID-19 pneumoniaInfections and infestations | 2/145 |
| PneumoniaInfections and infestations | 2/145 |
| Myasthenia gravis crisisNervous system disorders | 2/145 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/145 |
| AnaemiaBlood and lymphatic system disorders | 1/145 |
| Acute myocardial infarctionCardiac disorders | 1/145 |
| ArrhythmiaCardiac disorders | 1/145 |
| Event | Efgartigimod |
|---|---|
| HeadacheNervous system disorders | 36/145 |
| NasopharyngitisInfections and infestations | 20/145 |
| COVID-19Infections and infestations | 16/145 |
| DiarrhoeaGastrointestinal disorders | 13/145 |
| Urinary tract infectionInfections and infestations | 12/145 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/145 |
| PyrexiaGeneral disorders | 11/145 |
| NauseaGastrointestinal disorders | 9/145 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 8/145 |
| HypertensionVascular disorders | 8/145 |
The Safety Analysis set consisted of all participants who rolled over from ARGX-113-1704 and received \>=1 dose or part of a dose of efgartigimod in this study.
| Age, Continuous(years) | Efgartigimod |
|---|---|
| Mean | 47.0 ± 14.76 |
| Sex: Female, Male(Participants) | Efgartigimod |
|---|---|
| Female | 103 |
| Male | 42 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 11 |
| Black or African American | 5 |
| White | 126 |
| Multiple | 1 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod |
|---|---|
| Japanese | 10 |
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 126 |
| Anti-acetylcholine receptor antibodies (AChR-Ab) status(Participants) | Efgartigimod |
|---|---|
| AChR-Ab seropositive | 111 |
| AChR-Ab seronegative | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Jun 2022, 39 months.
Results were first posted in Jul 2023, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 39 months is above that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efgartigimod alfa